Policy
Terms of Service
These terms cover the pre-launch site only: the research corpus at titratelab.com and the waitlist form. The order-routing platform and checkout flow are not live yet, and will ship under a separate set of terms once they are.
Last updated: April 23, 2026.
1. Acceptance
By visiting titratelab.com, reading our published research, or submitting an email to our waitlist, you agree to these terms. If any part of them is something you can't live with, don't use the site. That's the whole acceptance mechanic.
We may update these terms over time. The version at the URL you're reading is the current one, with the "last updated" date above. Material changes get flagged at the top of the page for at least 30 days after they take effect.
2. What this site is
Right now, TitrateLab is a research-publication website. Long-form articles about the grey-market peptide economy, batch-quality data, and vendor analysis. Plus a waitlist form for people who want to know when the full platform opens.
It is not, today, a commerce platform. You can't buy anything here. You don't have an account. There is no checkout, no cart, no inventory, no shipping. The order-routing service described in our platform announcement is a thing we're building. It is not a thing you're using when you're on this site.
Everything in these terms applies to the site as it exists today. Separate terms will govern the platform when it launches.
3. Our content
The research articles, data visualizations, methodology notes, and written commentary on this site are our work product. Copyright TitrateLab, all rights reserved, with two carve-outs:
- You can share and cite freely with attribution and a link back to the source article. Quote a paragraph, screenshot a chart, link the piece in a forum thread. Normal journalistic fair-use behavior is welcome and the reason we publish.
- You cannot republish full articles on another site, wrap them in a paywall, feed them to a training corpus without permission, or strip attribution. If you want to syndicate or translate a piece in full, email us and we'll probably say yes.
The underlying batch-level data we cite (Finnrick panels, Janoshik verifications, public COAs) belongs to the labs and publishers that produced it. We aggregate and analyze. We don't claim ownership of the raw test results.
4. How you can use the site
Normal reading, sharing, and waitlist signup are fine. The following are not:
- No automated scraping of the research corpus without written permission. If you want the data, ask. If you're a journalist or researcher, we're friendly; if you're a competitor building a derivative database, we're less friendly but still reachable.
- No attempt to circumvent waitlist ordering. The position queue is first-come, first-served. Submitting multiple emails, automating signups, or otherwise gaming the Founding 100 / Early Access tiers will get your entries removed.
- No attempts to compromise the site itself. Probing for vulnerabilities without coordination, attempting to extract other users' waitlist data, or running DoS-shaped traffic against us. If you find a real security issue, email us and we'll thank you.
5. Disclaimers
This is the part that matters. Read it.
We do not give medical advice. Nothing on this site is a prescription, a treatment protocol, a dosing recommendation, or clinical guidance. Our research is journalistic analysis of a grey market. If you're making a health decision, that's between you, a licensed clinician, and whatever jurisdiction you live in.
Our grey-market commentary describes what we observe. When we write about vendor reputations, community sentiment, or batch-quality outcomes, we're reporting on observable activity in public forums, lab-test data, and enforcement records. A description of market behavior is not an endorsement of that behavior. We don't tell you to buy anything. We don't tell you not to. We describe what's happening and let you decide.
Research-peptide products are not FDA-approved for human use in most of the cases we cover. The legal status of possession, import, and research use varies by jurisdiction and changes over time. We write about that landscape. We don't make legal determinations for you.
The data we publish is best-effort, not audited truth. We source from public labs, vendor disclosures, and community-reported incidents. We correct the record when we're wrong, and we mark articles with revision dates. Don't treat any single chart as gospel without reading the methodology that produced it.
6. The waitlist
When you submit your email to the waitlist, here's what we will do with it:
- We'll email you once when the platform opens — the launch announcement with your access tier and next steps
- We'll email you once when the methodology page publishes — the scoring logic we use to rank vendors, so you can read it before you use the platform
- We'll email you once if the launch timeline shifts materially — if July slides to September, you'll hear about it once, not weekly
That's the full email budget before launch: up to three messages. No newsletter. No drip campaign. No partner promotions. No selling the list. If you want off earlier than launch, reply "remove" to any email we send you or use the unsubscribe link, and you're out of the database within 48 hours.
For the full data-handling picture — what we collect, who touches it, how long we keep it — see the Privacy Policy.
7. Limitation of liability
We publish the research in good faith and to the best of our ability. We can't promise it's perfect. To the extent permitted by law:
- We make no warranty that the site will be available at all times, free of errors, or continuously accurate
- We are not liable for decisions you make based on reading our content, including research, commerce, health, legal, or financial decisions
- Our total liability to any single user, for any claim arising from the pre-launch site, is capped at $100 or the amount you've paid us (zero, since we don't charge for the site), whichever is greater
If you're in a jurisdiction that doesn't allow this kind of liability limit, it applies to the maximum extent your jurisdiction allows and no further.
8. Changes to these terms
We may revise these terms. When we do:
- The "last updated" date at the top changes
- A banner goes up on the policy page for at least 30 days after a material change
- Your continued use of the site after the update means you accept the revised terms
If you don't accept a revision, stop using the site and reply "remove" to any waitlist email to clear your data.
9. Contact
Questions, pushback, takedown requests, press inquiries, security reports, or anything else that belongs in front of a human:
- General contact: hello@titratelab.com
- Legal + takedowns: legal@titratelab.com
- Security issues: security@titratelab.com
We're a Delaware LLC operating remotely. Physical mail address will be added once we have a registered agent worth naming publicly.
TitrateLab is under active legal review ahead of platform launch. These terms cover the pre-launch research site only. The platform terms — checkout, routing, consolidation, refunds, vendor relationships — will ship separately when the platform does. Slogan, for the record: experiment with confidence.